Biotechnology

Pharma manufacturer Mikart cuts the ribbon on a new Atlanta HQ while boosting bottling capacity by 50%, tackling industry demand and fueling local growth.

As it preps a first-in-human study for a deadly genetic heart disease, Nuevocor brings on gene therapy veteran Dr. Monica Shah to lead the charge.

Ascidian Therapeutics to present first human safety data for its Stargardt disease drug, a new RNA editing technology with broad potential for genetic diseases.

A new collaboration aims to merge drugs with AI-driven apps, creating a novel class of therapy that could revolutionize treatment, starting with rare cancers.

With gonorrhea becoming increasingly resistant to antibiotics, a new $2.6M grant fuels the development of a promising preventative vaccine platform.

Biotech firm Tr1X unveils promising data for its novel cell therapies, offering a scalable new approach to treating autoimmune diseases like MS and GvHD.

Dyno Therapeutics is using AI to design 'smart' viral vectors, promising safer, more effective treatments for untreatable genetic diseases.

Biotech firm Cellectis presents a new epigenetic platform that silences genes without cutting DNA, a potentially safer approach for cancer and liver disease.

Cambridge biotech to unveil AI-powered LNP platform at ASGCT 2026, targeting fat and T-cells to unlock new treatments for obesity and cancer.

Umoja Biopharma's UB-VV500 aims to revolutionize myeloma care by creating a dual-antigen CAR T therapy directly inside the patient's body.

A new therapy programs immune cells inside the body to fight disease. Sail Biomedicines is pioneering this approach to offer a potential cure for autoimmunity.

A new grant from Zymo Research aims to solve a key data problem in gut science, potentially unlocking the next wave of breakthroughs in personalized medicine.

New Phase 2a data reveals Oruka Therapeutics' ORKA-001 achieved complete skin clearance in nearly two-thirds of patients, positioning it as a potential game-changer.

With investments exceeding $1B, PCI Pharma Services is expanding its US sterile manufacturing, tackling supply chain risks and boosting domestic production.

A UK firm's breakthrough blood test for early breast cancer detection joins a prestigious EU network, aiming to personalize treatment and redefine diagnostics.

A Calgary startup's revolutionary wound care gel, already used in hospitals, is now being funded by the government for battlefield trauma applications.

A financially struggling healthcare firm makes a bold leap into neurotechnology, but can it compete with giants like Neuralink in the high-risk BCI race?

A new long-term deal for the INTERCEPT system highlights a critical shift towards proactive pathogen reduction to protect France's blood supply from global threats.

RedHill Biopharma flips a capital deficit to positive equity, driven by savvy partnerships for its drugs Talicia and Bekinda and a promising R&D pipeline.

In a key human trial, Sona Nanotech's heat-based therapy saw a 60% complete response in tumors for melanoma patients who had exhausted other options.